Table 3.
Patterns of failure after treatment for stage I/II extranodal NK-/T-cell lymphoma, nasal type.
| N | F/U years (median, range) |
Local failure (LF) |
Regional failure (RF) |
Distant failure (DF) |
||
|---|---|---|---|---|---|---|
| Non-l-ASP | EQD2 ≥ 40 Gy | 36 | 5.2 (0.5–18.6) | 4 (11 %) | 3 (8 %) (without LF) | 9 (25 %) (1 with LF, 1 with RF, 7 DF only) |
| EQD2 < 40 Gy | 4 | 8.4 (2.8–20.8) | 1 (25 %) | 0 | 1 (25 %) (with LF) | |
| l-ASP | EQD2 ≥ 40 Gy | 17 | 5.1 (0.6–11.3) | 4 (24 %) | 2 (12 %) (with LF) | 5 (29 %) (1 with LF, 2 with locoregional, 2 DF only) |
| EQD2 < 40 Gy | 19 | 5.0 (0.9–9.4) | 4 (21 %) | 0 | 0 |
F/U, follow-up; l-ASP, l-asparaginase-containing chemotherapy; EQD2, equivalent dose in 2 Gy fractions.